ArticleJournal of cancer research and clinical oncology2022
Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Biomarkers for Lung Nodule Risk Stratification: Are We There Yet?Diagnostics (Basel, Switzerland) · 2026Review
- CACs Recognition of FISH Images Based on Adaptive Mean Teacher Semi-supervised Learning with Domain-Knowledge Pseudo Label.Journal of imaging informatics in medicine · 2025Article
- Liquid biopsy in lung cancer.Breathe (Sheffield, England) · 2025Review
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- Precision patient selection for improved detection of circulating genetically abnormal cells in pulmonary nodules.Scientific reports · 2024Article
- Analytical validation of the LungLB test: a 4-color fluorescence in-situ hybridization assay for the evaluation of indeterminate pulmonary nodules.BMC pulmonary medicine · 2024Article
- Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features.Endocrine · 2024Article
- A Lightweight and Robust Framework for Circulating Genetically Abnormal Cells (CACs) Identification Using 4-Color Fluorescence In Situ Hybridization (FISH) Image and Deep Refined Learning.Journal of digital imaging · 2023Article
- The diagnostic value of circulating abnormal cells in early lung cancer.American journal of cancer research · 2023Article
- An efficient fluorescence in situ hybridization (FISH)-based circulating genetically abnormal cells (CACs) identification method based on Multi-scale MobileNet-YOLO-V4.Quantitative imaging in medicine and surgery · 2022Article
- Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.BMC cancer · 2022Article
- Clinical Analysis of 137 Cases of Ovarian Tumors in Pregnancy.Journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLung cancer is the leading cause of cancer-related death worldwide. The early detection of lung cancer is crucial for the diagnosis of this disease. Therefore, an effective and noninvasive method for the early diagnosis of lung cancer is urgently needed.
methodsTo evaluate the diagnostic performance of circulating genetically abnormal cells (CACs) in early lung cancer, a total of 63 participants who completed CAC detection by Zhuhai SanMed Biotech Inc. and obtained pathological results from January to December 2020 were included in our study; 50 patients had lung cancer and 13 patients had benign lung disease. The levels of lung cancer-related markers in peripheral blood and the chest computed tomography (CT) imaging characteristics of these patients were collected before pathological acquisition.
resultsThe positive rate of CAC was 90.0% in the lung cancer group and 23.1% in the benign lung disease group, and the difference was statistically significant (P < 0.01). The area under the receiver operating characteristic (ROC) curve of CAC was 0.837, the sensitivity was 90%, and the specificity was 76.9%. The area under the ROC curve and sensitivity were both higher than those of the combined or single serum tumor marker test.
conclusionsThis study preliminarily concludes that the CAC test, as a noninvasive test, has high sensitivity and specificity for the early diagnosis of lung cancer. This test is expected to help with the early detection of disease in lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.